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1. Introduction 
Postheparin plasma contains two separate lipolytic 
enzymes, lipoprotein lipase and hepatic lipase, which 
are released from vascular endothelial cells. The 
former is located in extrahepatic capillary beds and 
has a well-defined role in the catabolism of plasma 
triglycerides. The hepatic lipase has been recently 
shown to be located on the surface of hepatic endo- 
thelial cells [l] but the physiological function of this 
enzyme is still far from clear. Hepatic endothelial lipase 
can hydrolyze chylomicron and VLDL triglycerides 
in vitro [2] but its activity in postheparin plasma has no 
correlation to plasma triglyceride levels [3]. It has 
been suggested that hepatic lipase could be involved 
in the uptake of chylomicron remnants [4], inter- 
mediate density lipoprotein [5] or LDL [6] by the 
liver but there is little experimental evidence for any 
of these possibilities. 
We have recently purified the heparin-releasable 
lipase from rat liver perfusates [7] and used the 
enzyme preparation for production of antiserum. 
The availability of this anti-hepatic lipase serum 
offered a good opportunity to study the function of 
the enzyme by searching whether plasma lipoproteins 
are influenced by specific inhibition of the hepatic 
endothehal lipase in vivo. 
Abbreviations: HDL, high density lipoprotein; HEL, hepatic 
endothelial ipase (previous term ‘hepatic lipase’ has not been 
used for the heparin-releasable lipase because the liver con- 
tains a number of other lipolytic enzymes); LDL, low density 
lipoprotein; VLDL, very low density lipoprotein 
2. Methods 
2 .l . Animals 
Male Sprague-Dawley rats (300-400 g) were used. 
Polyethylene catheters (PE-50, Clay Adams, USA) 
were inserted into jugular vein and carotid artery 
under phenobarbital nesthesia (Nembutal@ 25 mg/kg 
body wt) and the animals were allowed to regain full 
consciousness over 2-3 h. During the experiment the 
rats were immobilized into small cages and they 
received water ad libitum but no food. The injections 
were given through the venous cannula while blood 
was sampled through the arterial catheter. Adult 
white New Zealand rabbits were used for production 
of the antiserum. 
2.2. Preparation of an ti-hepatic lipase serum 
Heparin-releasable hepatic lipase was purified from 
rat liver heparin perfusate by chromatography on 
heparin-Sepharose column followed by ammonium 
sulphate precipitation and gel filtration on Ultrogel 
AcA 34 as described [7]. The purified enzyme 
exhibited a single major band in polyacrylamide gel 
electrophoresis and its specific triglyceride lipase 
activity was 5 mmol FFA .h-’ mg-’ which is 
54-times higher than that of the original perfusate. 
For production of antiserum 5-l 0 pg enzyme 
protein was mixed with equal volume of complete 
Freund’s adjuvant and injected subcutaneously into 
rabbits at 4 week intervals. After 3-4 immuniza- 
tions the antiserum showed high inhibitory titres 
against rat postheparin plasma hepatic lipase with- 
out having any effect on the lipoprotein lipase 
activity of the same plasma. A control serum was 
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obtained from normal non~m~ized rabbits. Lipo- 
proteins were removed from both anti-HEL serum 
and control rabbit serum before their use for the 
experiments. The sera were mixed with NaCl-KBr 
solution to produce a solvent density of 1.2 1 g/ml 
and centrifuged in Sorvall OTD-2 ultracentrlfuge 
with 42 000 rev./mm for 40 h. The bottom layer 
was separated and extensively dialyzed against 0.15 M 
NaCl at +4’C. The anti-hepatic lipase activity of the 
antiserum was completely recovered in this fraction. 
2 .? . Assay of lipase activities 
The assay of triglyceride lipase activity was based 
on measurement of the release of labeled free oleic 
acid from a gum arabic stabilized sonicated emulsion 
of triolein and tri [ 1-14C] oleoylglycerol. Details of 
the preparation of substrate, incubation conditions 
and separation of free oleic acid from unhydrolyzed 
substrate were exactly as described [8]. In post- 
heparin plasma the hepatic lipase was defined as the 
activity present at 1 ,O M NaCl without addition of 
serum; respectively, the lipoprotein lipase was taken 
as the activity measured at 0.15 M NaCl after incuba- 
tion of the sample with anti-hepatic lipase serum [S]. 
2.4. Preparation of postheparin plasma 
Non-fasting conscious rats were given an intra- 
venous bolus of 500 IU heparin/kg body wt. After 
2 mm, 1 ml blood was withdrawn through arterial 
cannula, plasma was separated and used for lipase 
assays within the same day. 
2.5. seminal meth~s 
Serum was separated by cen~fugation at +4”C 
and stored at this temperature. Lipoproteins were 
isolated by sequential ultracentrifugation atsolvent 
densities of 1.006 and 1.063 g/ml as in [9]. A Sorvall 
OTD-2 ultracentrifuge and Beckman Ti-50 angle head 
rotor were used. VLDL was separated at 1.006 g/ml 
by ultracentrifugation with 42 000 rev./mm at t2”C 
for 18 h. The density of the infranate was adjusted 
to 1.063 g/ml by NaCl-KBr solution and the LDL 
was brought o the surface by ultracentrifugation for 
20 h. The 1.063 infranate was taken to represent 
HDL. The recovery of each lipid in the three lipo- 
protein fractions varied from 93-100% of the 
corresponding total serum value. A correction for 
recovery was made. 
Cholesterol was determined by an enzymatic 
method [lo] using a commercial kit (Boehringer 
Mannheim). Phospholipids were measured according 
to [ 111, triglycerides by a Technicon Autoanalyzer 
[ 121 and protein by the Lowry method [ 131. 
2.6. Statistical analyses 
All values are given as means f SEM. The signi- 
ficance of differences was calculated using the two- 
tailed Student’s t-test. 
3. Results 
3 .l . Effect of an ti-hepatic lipase serum injection on 
postheparin plasma lipolytic activities 
To determine the degree, duration and specificity 
of inhibition of hepatic lipase by the antiserum in vivo 
unanesthetized rats were given 1.5 ml of the lipo- 
protein-free anti-HEL serum or control serum as a 
single intravenous injection. Postheparin plasma was 
then obtained at various time intervals, once from 
each animal. The amount of antiserum used per 
animal was able to completely inhibit the hepatic 
triglyceride lipase activity of 42 ml rat postheparin 
plasma in vitro. After injection of the antiserum no 
Fig.1. Postheparin plasma lipoprotein lipase (open circles) 
and hepatic lipase (black circles) activities after intravenous 
injection of anti-hepatic lipas serum (G~IG~W) or normal 
rabbit serum (squares) 5 min before the zero time. Each 
point represents a mean value obtained from 3 rats. 
385 
Volume 104, number 2 FEW LETTERS August 1979 
hepatic lipase activity codd be detected in post- 
heparin plasma t I h whereafter the activity 
rose progressivefy, being 20% and 70% of the corre- 
sponding control value at 2 h and 5 h, respectively 
(fig.1). No significant change occurred in the Xipo- 
protein lipase activity of postheparin plasma. 
3.2 ~ Effect of anti-hepatic lipase serum oxi lipo- 
proteins 
Ten unanesthetized rats with indwelling venous 
and arterial catheters were given 2 intravenous 
injections of lipoprotein-free anti-HEL serum (each 
dose neutralizing hepatic Iipase in 42 ml pos~ep~~ 
plasma) at 2.5 h interval. Another 10 rats served as 
controls and received similar volumes of lipoprotein= 
free normal rabbit serum. The concentrations of
cholesterol, phospholipids and triglycerides in the 
3 major Serum lipoprotein fractions were determined 
in samples drawn 5 h after the first antiserum injec- 
tion. The results appear in fig.2. The animals injected 
with the antiserum had significantly higher concen- 
trations of LDL and HDL cholesterol and phospho- 
lipids than the control rats. The mean total cholesteroi 
level was 49% higher (I05 mg/loO ml versus 70 mgf 
I00 mf,p < O.OOf) and the mean totaI phospholipid 
28% higher (188 i 7 mg/IOO mI versus 147 f 5 mg( 
100 ml, p < 0.001) in the antiserum group than in the 
control group. The trigIyceride levels in whale serum 
and in all lipoprotein fractions were similar in the two 
groups. The cholesterollphospholipid ratio in whole 
serum and in the lipoproteins was slightly higher in 
antiserum-treated rats than in the controls but the 
differences were not significant at 5% level. The pro- 
tein concentration was determined only in LDL and 
it was similar in antiserum (33.0 f 2.4 mgflO0 ml) 
and control (30.5 f 3.2 mg/lOO ml> animals. 
4. Discussion 
The heparin-releasable hepatic lipase of rat has 
been recently shown to be located on the luminal 
surface of the endothelial cells lining the liver sinu- 
soids [ 11. Such a localization is consistent with the 
extremely rapid release of the enzyme by heparin 
Furthermore, the close contact of the enzyme with 
circulating blood suggests hat the hpase has a physio- 
logical role in the removal of plasma lipoproteins or 
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Fig.2. Cholesterol, phospholipid and trigIyceride cortcentra- 
tjons in plasma VLDL, LDL and HDL of rats given either 
anti-hepatic lipase serum (n = 10, hatched columns) or normal 
rabbit serum (n = 10, white columns) at 5 and 2.5 h before 
blood sampling. The bars indicate SEM. * = p C 0.05, ** = 
p < 0.01, **I = p < 0.001 for the difference between group 
means. N.S. = not significant. 
of their constituent lipids, the enzyme being thus 
functionally anaIogous to lipoprote~ lipase which is 
located in the vascular endo~elium of extrahepatic 
tissues. 
The present results upport he above hypothesis. 
Inhibition of HEL by a specific antiserum in vivo was 
followed by significant increases of cholesterol and 
phospholipid concentrations in LDL and HDL. On 
the other hand, the WEL antiserum did not have any 
effect on triglyceride concentration i  the lipopro- 
teins and also the protein concentration i  LDL (not 
measured in NDL) remained unaffected. These fmd- 
ings suggest that HEL could be an enzyme which by 
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gome mechanism removes part of cholesterol and 
phospholipids from LDL and HDL particles during 
their passage through the liver. If apoproteiu is not 
simultaneously removed the density of the lipopro- 
tein particles must increase in this process. This might 
involve transformation of LDLr to LDL, and of HDL, 
to HDLJ. Opposite changes would thus be produced 
by HEL antiserum and it remains to be investigated 
whether this is the case. Anyway, by density criteria 
the lipoproteins of ~t~~~rn-treated rats were still 
LDL resp. HDL_ 
There is no direct proof for the claim that the 
observed rise of LDL and HDL cholesterol and phos- 
phalipids of the antiserum-treated rats was accounted 
far by the interference of the HEL-antiserum with 
the removal of these lipids but this seems to be the 
most plausible xplanation. In a similar experiment 
anti-lipoprotein lipase serum given intravenously to 
roosters completely inhibited the catabolism of VLDL 
triglycerides and caused their accumulation i to 
plasma [141. That the hepatic endothelial cells have a 
role in the metabolism of LDL and HDL is also sug- 
gested by the finding that after a~istra~ion of 
iod~e-labeled LDL or HDL into rat the protein 
radioactivity accumulates into nonparenchymal liver 
cells rather than into hepatocytes [ 151. 
Our results are also consistent with previous data 
indicating that cholesterol is taken up by the liver 
from both LDL and HDL [ 16,171. Thus, the concen- 
tration of LDL (1 .O 1% 1.063 g/ml) esterified chol- 
esterol was shown f16f in man to be lower in hepatic 
vein than in artery. A corresponding gradient could 
not be found for HDL cholesterol but this may be 
difficult to demonstrate because of the relatively 
small concentration of HDL ~hole~erol in the plasma 
and also due to splanchnic secretion of HDL. Hepatic 
cholesterol synthesis can be shown ] 173 in rats to be 
suppressed by infusion of either LDL or HDL, which 
must imply a hepatic uptake of cholesterol from 
these lipoproteins. There are no published ata on 
the uptake of phospholipids from lipoproteins by the 
liver. 
The mechanism by which the HEL could mediate 
the uptake of cholesterol from lipoproteins is not 
clear. One possibility is that the high phospholipase 
activity of HEL [lg] could be responsible for first 
step in this process, viz. breakdown of the surface 
phospholipids of the lipoproteins. Hepatic non- 
parenchymal cells have also a high cholesteral ester 
hydrol&eao$ivitv 1191 but it is not known whether 
this is located in theend&e$alcel.ls. The finding 
that LDL apoprotein level was not influenced by 
HELantiserum is compatible with data indicating 
only minimal uptake and degradation of LDL protein 
by the liver [ 16,201. A concept proposing the shattle 
of LDL and HDL particles in the transport of chol- 
esterol and phospho~pids between peripheral tissues 
(including peripheral catabolism of triglyceride-rich 
lipoproteins) and the liver could also account for 
the discrepancies found earlier between the ttansport 
rates of cholesterol and apoproteins in LDL and HDL. 
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